Companies /Healthcare
Boston Scientific Corp
NYSE: BSX Medical Devices
$42.73
▲ $0.69 (+1.64%) today
Markets closed · 7:52pm ET

Boston Scientific (BSX) Q2 2026 Earnings

Reported Jul 29, 2026, 6:33am ET · SEC source
$0.86
Beat +3.86%
EPS · est. $0.83
$5.4B
Beat +1.42%
Revenue · est. $5.4B
−3.7%
Trailing market
BSX vs S&P since report
6 quarters
Consecutive EPS beats

How Did BSX Stock React to Q2 2026 Earnings?

% change · around the report
−8%−4%0+4%Jul 29Jul 30report 6:33am ETearnings−0.5%−3.2%
−8%−4%0+4%Jul 29Jul 30earnings−0.5%−3.2%
BSX −3.2%S&P 500 −0.5%
−8%−4%0+4%Jul 29Jul 30report 6:33am ETearnings+0.5%−3.2%
−8%−4%0+4%Jul 29Jul 30earnings+0.5%−3.2%
BSX −3.2%NASDAQ +0.5%
−6%−3%0+3%Jul 28Aug 6report 6:33am ETearnings+3.9%+3.0%
−6%−3%0+3%Jul 28Aug 6earnings+3.9%+3.0%
BSX +3.0%S&P 500 +3.9%
−4%0+4%+8%Jul 28Aug 6report 6:33am ETearnings+5.6%+3.0%
−4%0+4%+8%Jul 28Aug 6earnings+5.6%+3.0%
BSX +3.0%NASDAQ +5.6%
−0.04%
Day of report
−0.09%
Next session
+3.69%
One week
+1.74%
30 days

S&P 500 over the same 30 days: +5.47%.

Did BSX Beat Earnings? Q2 2026 Results

Yes. Boston Scientific reported Q2 2026 earnings of $0.86 a share on Jul 29, 2026, beating the $0.83 consensus estimate by 3.9%. Revenue was $5.4B against a $5.4B estimate.

Boston Scientific posted a clean beat across both top and bottom lines in Q2 2026, extending its EPS consensus beat streak to five consecutive quarters as adjusted earnings of $0.86 per share cleared the $0.83 estimate by 3.86% and rose sharply from $0.75 in the year-ago period. Revenue of $5.44 billion grew 7.5% year over year, edging past the $5.37 billion consensus by 1.42%, with the Cardiovascular segment serving as the primary engine, delivering 8.3% reported sales growth and helping lift GAAP net income to $907 million, or $0.61 per diluted share, from $797 million a year ago. A standout within the broader portfolio was the Neuromodulation business, which grew 12.7% on a reported basis, while the FARAPULSE pulsed field ablation system continued to generate positive clinical momentum. The strong quarter arrives alongside a global restructuring plan targeting $500 million in annual cost savings, as management looks to sharpen its operational profile; for full-year 2026, Boston Scientific guided for organic revenue growth of 5% to 6% and adjusted EPS of $3.28 to $3.32.

Key Takeaways
  • Cardiovascular segment growth of 8.3% reported driven by strong demand
  • Neuromodulation growth of 12.7% reported was the fastest growing product line
  • Asia Pacific region grew 11.2% and Latin America/Canada grew 22.4% on a reported basis
  • Category leadership strategy and disciplined execution across the portfolio

“Our team delivered a solid quarter while continuing to navigate a dynamic environment. We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities, and we remain confident in Boston Scientific's long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians.”

Boston Scientific CEO, on the earnings call

What Is Boston Scientific's Outlook?

For full year 2026, Boston Scientific estimates net sales growth of approximately 5.5% to 6.5% on a reported basis and 5% to 6% on an organic basis, with adjusted EPS of $3.28 to $3.32. For Q3 2026, the company estimates net sales growth of approximately 3% to 5% on both a reported and organic basis, with adjusted EPS of $0.80 to $0.82.

BSX YoY Financials

Q2 2026 vs Q2 2025 · SEC filings Q2 2025 Q2 2026
$0$2.0B$4.0B$5.1B$5.4BRevenue$3.4B$3.8BGross Profit$819.0M$1.2BOperating Income$793.0M$907.0MNet Income
$0$2.0B$4.0BRevenueGross ProfitOperating IncomeNet Income
BSX income statement, Q2 2026 versus Q2 2025
Metric Q2 2026 Q2 2025 Year over year
Revenue $5.4B $5.1B +7.5%
Gross Profit $3.8B $3.4B +12.4%
Operating Income $1.2B $819.0M +43.8%
Net Income $907.0M $793.0M +14.4%

BSX Revenue by Segment

Cardiovascular$3.6B+8.3%
Cardiology
MedSurg$1.8B+5.9%
Endoscopy$793.0M+7.6%
Urology$684.0M+1.1%
Peripheral Interventions
Neuromodulation$341.0M+12.7%

BSX Revenue by Geography

United States$3.4B+6.2%
EMEA$932.0M+6.1%
Asia Pacific$878.0M+11.2%
Latin America$206.0M+22.4%

When Does Boston Scientific Report Next?

Expected report date
Before the open
Release timing

Figures from SEC filings and company reports. Not investment advice.